Turnstone biologics corp. reports first quarter 2024 financial results and provides recent business highlights

San diego, may 13, 2024 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (selected til) therapy, today reported financial results for the first quarter ended march 31, 2024, and provided recent business highlights. “we are excited about the therapeutic potential of our pipeline of next-generation selected til therapies,” said sammy farah, m.b.a.
TSBX Ratings Summary
TSBX Quant Ranking